Domov › Myelofibróza › Kalifornia
Klinické štúdie Myelofibróza v štáte Kalifornia
21 štúdií pre Myelofibróza hľadá účastníkov v zariadeniach v štáte Kalifornia.
Mestá v štáte Kalifornia
- Baldwin Park9 štúdií
- Mountain View7 štúdií
- Los Angeles6 štúdií
- Irvine5 štúdií
- Sacramento3 štúdií
- Orange3 štúdií
- San Diego3 štúdií
Oficiálny text štúdie (anglicky)
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- City of Hope, Duarte
- University of Southern California, Los Angeles
- Hoag Family Cancer Institute, Newport Beach
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT04176198A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
- UCLA Ronald Reagan Medical Center, Los Angeles
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT07469891A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Los Angeles Cancer Network, Glendale
- Cancer and Blood Specialty Clinic, Whittier
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT07623161A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
- Stanford Cancer Institute Palo Alto, Palo Alto
- a 1 ďalších
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT06661915Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- City of Hope - Duarte, Duarte
- City of Hope - Lennar, Irvine
- UCLA, Los Angeles
- a 1 ďalších
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT05320198A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- Stanford Cancer Institute, Palo Alto
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 17. 9. 2026 · NCT06343805TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
- Stanford University, Palo Alto
Prebieha náborFáza 1
Vek 18 až 80 · Všetky pohlavia · Aktualizované 17. 8. 2026 · NCT07302776A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
- Stanford University, Palo Alto
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 6. 8. 2026 · NCT07008118A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- City of Hope Medical Center, Duarte
Prebieha náborFáza 1Vítaní zdravých dobrovoľníkov
Vek 18 až 75 · Všetky pohlavia · Aktualizované 28. 7. 2026 · NCT07020533Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- City of Hope-Lennar Foundation Cancer Center, Irvine
- Usc Norris Comprehensive Cancer Center, Los Angeles
- UCLA Medical Hematology & Oncology, Los Angeles
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 7. 2026 · NCT07441694A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
- City of Hope Center, Duarte
- UC Davis Comprehensive Cancer Center, Sacramento
- UC San Diego Moores Cancer Center, San Diego
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 20. 7. 2026 · NCT07250646Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 4. 5. 2026 · NCT07281781A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- City of Hope Medical Center, Duarte
- Stanford Cancer Institute, Palo Alto
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 17. 4. 2026 · NCT06034002Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 27. 3. 2026 · NCT06063486A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- City of Hope, Duarte
- Stanford, Palo Alto
Prebieha náborFáza 2
Vek 18 až 66 · Všetky pohlavia · Aktualizované 17. 3. 2026 · NCT06859424CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- City of Hope Medical Center, Duarte
Prebieha náborFáza 2Vítaní zdravých dobrovoľníkov
Vek 18 až 75 · Všetky pohlavia · Aktualizované 10. 3. 2026 · NCT06059391An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
- University of California, Irvine, Irvine
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 10. 3. 2026 · NCT05123365A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- City of Hope - Duarte Main Site, Duarte
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 12. 2. 2026 · NCT05980806SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duarte
- Massive Bio SYNERGY-AI site, Irvine
- Massive Bio SYNERGY-AI site, La Jolla
- a 3 ďalších
Prebieha náborObservačná štúdia
Všetky vekové kategórie · Všetky pohlavia · Aktualizované 28. 10. 2025 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- UC San Diego Moores Cancer Center, La Jolla
- UCLA Hematology/Oncology Clinic - Los Angeles, Los Angeles
- Scripps Health, Prebys Cancer Center, San Diego
- a 1 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2025 · NCT06479135Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
- UC Davis Health, Sacramento
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 13. 4. 2025 · NCT05423691Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.